Celon Pharma SA Market Cap ($183.12 Million)
Market Cap & Net Worth: Celon Pharma SA (CLN)
Celon Pharma SA market cap. Celon Pharma SA (WAR:CLN) has a market capitalization of $183.12 Million (zł665.39 Million) as of November 1, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #16679 globally and #108 in its home market, demonstrating a -12.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Celon Pharma SA's stock price zł17.10 by its total outstanding shares 38911500 (38.91 Million). Also see Celon Pharma SA (CLN) cash flow conversion for how efficiently the company converts equity into cash flow.
Celon Pharma SA Market Cap History (2016–2026)
Celon Pharma SA market cap history from 2016 to 2026. Data shows change from $249.72 Million to $183.12 Million (-2.14% CAGR). Check Celon Pharma SA (CLN) stock price for real-time trading data and today's change.
Index Memberships
Celon Pharma SA is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
mWIG40
MWIG40
|
$75.09 Billion | 0.24% | #33 of 40 |
Weight: Celon Pharma SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Celon Pharma SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Celon Pharma SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CLN net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.04x
Celon Pharma SA's market cap is 1.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $249.72 Million | $128.78 Million | $37.81 Million | 1.94x | 6.61x |
| 2017 | $366.60 Million | $107.12 Million | $25.62 Million | 3.42x | 14.31x |
| 2018 | $321.78 Million | $125.24 Million | $29.70 Million | 2.57x | 10.84x |
| 2019 | $411.16 Million | $102.25 Million | $11.93 Million | 4.02x | 34.45x |
| 2020 | $421.00 Million | $157.45 Million | -$917.00K | 2.67x | N/A |
| 2021 | $344.79 Million | $196.09 Million | -$11.61 Million | 1.76x | N/A |
| 2022 | $148.52 Million | $161.91 Million | -$39.28 Million | 0.92x | N/A |
| 2023 | $164.72 Million | $213.92 Million | -$28.12 Million | 0.77x | N/A |
| 2024 | $283.25 Million | $176.62 Million | -$34.45 Million | 1.60x | N/A |
| 2025 | $217.93 Million | $209.80 Million | -$79.36 Million | 1.04x | N/A |
Competitor Companies of CLN by Market Capitalization
Companies near Celon Pharma SA in the global market cap rankings as of November 1, 2026. Also see balance sheet size of Celon Pharma SA for a full breakdown of the balance sheet.
Key companies related to Celon Pharma SA by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Celon Pharma SA (2016–2026)
Market capitalization of Celon Pharma SA from 2016 to today. Between 2016 and today, Celon Pharma SA's market cap moved from $249.72 Million to $ 183.12 Million, with a yearly change of -2.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł183.12 Million | -15.97% |
| 2025 | zł217.93 Million | -23.06% |
| 2024 | zł283.25 Million | +71.96% |
| 2023 | zł164.72 Million | +10.90% |
| 2022 | zł148.52 Million | -56.92% |
| 2021 | zł344.79 Million | -18.10% |
| 2020 | zł421.00 Million | +2.39% |
| 2019 | zł411.16 Million | +27.78% |
| 2018 | zł321.78 Million | -12.23% |
| 2017 | zł366.60 Million | +46.81% |
| 2016 | zł249.72 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Celon Pharma SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $183.12 Million USD |
| MoneyControl | $183.12 Million USD |
| MarketWatch | $183.12 Million USD |
| marketcap.company | $183.12 Million USD |
| Reuters | $183.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Celon Pharma SA
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.